Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Section:Activating mutations in BRAFV600 are present in 40%-50% of patients with melanoma, and mutant-specific inhibition with small molecule inhibitors of BRAF and MEK are...

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be...

  • 1560688043119595521 Profile photo of Madelyn

    6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc - view on twitter

PURPOSE Clinical trial evidence is routinely evaluated for initial drug approvals, yet the benefit of indication extensions remains uncertain. This study evaluates the clinical...

PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) Item Library is an interactive online platform currently composed of 950 unique items...

PURPOSE On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation...

PURPOSE A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch...

  • 1560642752823660545 Profile photo of Madelyn

    In a randomized phase II study of maintenance rucaparib after chemotherapy in 40 pts with DNA repair-deficient urothelial carcinoma, mPFS was 35.3 vs 15.1 weeks with placebo (HR 0.53; 80% CI, 0.30 to 0.92; P = 0.07): https://t.co/C40Q9wuqkh #blcsm #medonc #caxtx #uroonc - view on twitter

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid...

Section:Total neoadjuvant therapy (TNT) is now recognized as the preferred standard for the treatment of locally advanced rectal cancer.1 Using this approach, all nonsurgical...

PURPOSE Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest...

  • 1560574797842567170 Profile photo of Madelyn

    In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp - view on twitter

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine,...

  • 1560506615568252928 Profile photo of Madelyn

    Higher iPET- with AVD-BV compared with ABVD in early unfav #Hodgkin • BREACH study, rand Ph2, 170pts • 4x ABVD v 4x AVD-BV with RT • iPET- 75.4% v 82.3% (primary EP) • 2y PFS 92.6% v 97.3% Great work by Fornecker et al @LysaLymphoma. https://t.co/rhcwZW2tDu - view on twitter